ClinicalTrials.gg
Not yet recruitingNCT07400094NeoCamre-HNUpdated Feb 10, 2026

Neoadjuvant Chemoimmunotherapy (Camrelizumab + Paclitaxel + Carboplatin) for Resectable HNSCC

A Phase 2 interventional study of Camrelizumab and Paclitaxel in Squamous Cell Carcinoma of Head and Neck, Laryngeal Neoplasms and Oral Cavity Neoplasm, sponsored by National Medical Research Radiological Centre of the Ministry of Health of Russia. Not yet recruiting at 1 site in Russia. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-02-10.

Sponsored by National Medical Research Radiological Centre of the Ministry of Health of Russia · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies testing camrelizumab in Squamous Cell Carcinoma of Head and Neck — 8 open to participants now, 8 under way, 2 of them phase 3. camrelizumab · Squamous Cell Carcinoma of Head and Neck.

Planned enrollment
6th of 13
50 · median 46
Started
2026
with 1 other
Phase 2
11 of 13
6 open now
Registered
11th of 13
by date
Lead sponsor
1 of 13
National Medical Research Radiological Centre of the Ministry of Health of Russia

Among the 13 studies testing camrelizumab in Squamous Cell Carcinoma of Head and Neck, this one is the 6th largest by planned enrollment, is one of 2 that started in 2026, is one of 11 in phase 2, and was the 11th registered.

Squamous Cell Carcinoma of Head and Neck

2,023 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

8 of the 13 studies testing camrelizumab in Squamous Cell Carcinoma of Head and Neck are open now, in 2 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

About camrelizumab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 434 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 310 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing camrelizumab in Squamous Cell Carcinoma of Head and Neck, or all of them as a file.
02

Study summary

This phase II study evaluates the efficacy and safety of neoadjuvant chemoimmunotherapy consisting of camrelizumab (PD-1 inhibitor), paclitaxel, and carboplatin in patients with resectable locally advanced (Stage III-IVA) squamous cell carcinoma of the oral cavity and/or larynx.

Fifty patients will receive 3 cycles of therapy (camrelizumab 200 mg IV, paclitaxel 175 mg/m2 IV, carboplatin AUC6 IV, Day 1 every 21 days) followed by radical surgery 4-6 weeks later. Patients are then stratified to risk-adapted adjuvant therapy based on pathological findings (radiation or chemoradiation with cisplatin if adverse features present).

The primary endpoint is the pathological complete response (pCR) rate and major pathological response (MPR, \<10% viable tumor cells) rate at surgery. Secondary endpoints include objective response rate (ORR) by imaging (MRI/PET-CT), correlation of PET-CT metabolic response with pathological response, proportion requiring adjuvant chemoradiation, and 3-year event-free survival compared to historical controls.

Study period: 2026-2029.

Read the detailed description

Investigator-initiated, single-arm, phase II study conducted at P.A. Hertsen Moscow Oncology Research Institute. Protocol approved by Local Ethics Committee (#1187/132).

03

Conditions studied

  • Squamous Cell Carcinoma of Head and Neck
  • Laryngeal Neoplasms
  • Oral Cavity Neoplasm

Keywords

  • Head and Neck Squamous Cell Carcinoma
  • Neoadjuvant Therapy
  • Camrelizumab
  • Paclitaxel
  • Carboplatin
  • Pathological Complete Response
  • PD-1 Inhibitor
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed squamous cell carcinoma of the oral cavity and/or larynx, Stage III-IVA (cT1-2N1-2M0, cT3-4aN0-2M0)
  • Resectable disease planned for surgical treatment
  • Age 18-75 years
  • No prior antitumor therapy for the current diagnosis
  • Tumor sample available for expression assessment
  • No other in anamnesis (except basal cell carcinoma of skin and carcinoma in situ of cervix)
  • Absence of comorbidities preventing systemic chemotherapy and immunotherapy

Exclusion criteria

Exclusion Criteria:

  • Patient refusal to undergo planned treatment
  • Protocol violations not related to medical indications
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Neoadjuvant Chemoimmunotherapy

    Patients receive 3 cycles of camrelizumab + paclitaxel + carboplatin followed by surgery. Number of Participants: 50 (Anticipated)

    Drug: Camrelizumab · Drug: Paclitaxel · Drug: carboplatin · Procedure: Radical Surgery

Interventions

  • 200 mg IV on Day 1, every 21 days for 3 cycles

    Also known as: SHR-1210

  • 175 mg/m² IV on Day 1, every 21 days for 3 cycles

    Also known as: Taxol

  • AUC 6 IV on Day 1, every 21 days for 3 cycles

    Also known as: Paraplatin

  • ProcedureRadical Surgery

    Standard radical resection 4-6 weeks after neoadjuvant therapy

06

What researchers measure

Primary outcomes

  1. Pathological Complete Response (pCR) Rate

    Rate of complete pathological response (absence of viable tumor cells in resected specimen)

    Time frame: At the time of surgery (approximately 10-12 weeks from baseline)

  2. Major Pathological Response (MPR) Rate

    Rate of major pathological response (\<10% viable tumor cells in resected specimen)

    Time frame: At the time of surgery (approximately 10-12 weeks from baseline)

Secondary outcomes

  1. Objective Response Rate (ORR)

    Rate of objective response by imaging (MRI/PET-CT) compared to historical TPF control

    Time frame: After 3 cycles of neoadjuvant therapy (approximately 9 weeks)

  2. 3-Year Event-Free Survival (EFS)

    EFS compared to historical control (surgery + RT/CRT)

    Time frame: 3 years from enrollment

  3. Incidence of Adverse Events

    Safety profile compared to standard TPF induction chemotherapy

    Time frame: From first dose until 30 days after surgery

  4. Proportion Requiring Adjuvant Chemoradiation

    Patients needing post-op CRT due to adverse pathological features vs historical control

    Time frame: At the time of surgery

07

Study locations

1 site
  • P.A. Hertsen Moscow Oncology Research Institute
    Moscow, Russia
    • Larisa V. Bolotina, MD, PhD · Contactlbolotina@yandex.ru · +79039686637
    • Maxim S. Ruban, MD · Contactruban.m.s@yandex.ru · +79204335470
    • Larisa V. Bolotina, MD, PhD · Principal investigator
    • Tatiana I. Deshkina, MD, PhD · Sub investigator
    • Andrey P. Polyakov, MD, PhD · Sub investigator
    • Maxim S. Ruban, MD · Sub investigator
08

References and documents

Publications

  • Wu D, Li Y, Xu P, Fang Q, Cao F, Lin H, Li Y, Su Y, Lu L, Chen L, Li Y, Zhao Z, Hong X, Li G, Tian Y, Sun J, Yan H, Fan Y, Zhang X, Li Z, Liu X. Neoadjuvant chemo-immunotherapy with camrelizumab plus nab-paclitaxel and cisplatin in resectable locally advanced squamous cell carcinoma of the head and neck: a pilot phase II trial. Nat Commun. 2024 Mar 11;15(1):2177. doi: 10.1038/s41467-024-46444-z. PubMed 38467604 ↗

Individual participant data

Plan to share: No — This is an investigator-initiated, single-center study conducted in Russia. Individual participant data will not be shared due to patient confidentiality requirements and institutional data protection policies.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2026; primary completion for Feb 2029, 36 months later.

Of 299 non-industry phase 2 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 85. This study's planned 36 months is below that.

Counting every sponsor, half of 366 studies reached it within 53 months; a quarter within 35 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2026
First posted
Feb 10, 2026
StartEst.
Feb 2026
Primary completionEst.
Feb 2029
CompletionEst.
Feb 2029
Last update
Feb 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07400094
Lead sponsor
National Medical Research Radiological Centre of the Ministry of Health of Russia
Responsible party
Sponsor
First posted
Feb 10, 2026
Start date
Feb 2026 (estimated)
Primary completion
Feb 2029 (estimated)
Completion
Feb 2029 (estimated)
Last update
Feb 10, 2026

Study contacts

Larisa V. Bolotina, MD, PhD
Contact
lbolotina@yandex.ru
+79039686637
Maxim S. Ruban, MD
Contact
ruban.m.s@yandex.ru
+79204335470
Larisa V. Bolotina, MD, PhD
study chair · P.A. Hertsen Moscow Oncology Research Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Camrelizumab · Paclitaxel · Carboplatin

Start the discussion